These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 39053617)

  • 1. A case of severe pulmonary exacerbation in a young patient with cystic fibrosis in the era of CFTR modulators.
    Lanfranchi C; Rizza C; Russo MC; Borzani I; Angileri SA; Nazzari E; Alicandro G; Blasi F; Daccò V
    Int J Infect Dis; 2024 Oct; 147():107190. PubMed ID: 39053617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is Obesity a Problem in New Cystic Fibrosis Treatments?
    Solís-García M; García-Clemente MM; Madrid-Carbajal CJ; Peláez A; Gómez Punter RM; Eiros Bachiller JM; Girón Moreno RM
    Nutrients; 2024 Sep; 16(18):. PubMed ID: 39339703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence and evolution of
    Armbruster CR; Hilliam YK; Zemke AC; Atteih S; Marshall CW; Moore J; Koirala J; Krainz L; Gaston JR; Lee SE; Cooper VS; Bomberger JM
    mBio; 2024 May; 15(5):e0051924. PubMed ID: 38564694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple Therapy for Cystic Fibrosis
    Barry PJ; Mall MA; Álvarez A; Colombo C; de Winter-de Groot KM; Fajac I; McBennett KA; McKone EF; Ramsey BW; Sutharsan S; Taylor-Cousar JL; Tullis E; Ahluwalia N; Jun LS; Moskowitz SM; Prieto-Centurion V; Tian S; Waltz D; Xuan F; Zhang Y; Rowe SM; Polineni D;
    N Engl J Med; 2021 Aug; 385(9):815-825. PubMed ID: 34437784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
    Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
    Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unmasking catamenial hemoptysis in the era of CFTR modulator therapy.
    Montemayor K; Claudio AT; Carson S; Lechtzin N; Christianson MS; West NE
    J Cyst Fibros; 2020 Jul; 19(4):e25-e27. PubMed ID: 31987762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del/CFTR variant genotype after elexacaftor/tezacaftor/ivacaftor treatment.
    Castaldo A; Iacotucci P; Bagnasco S; Fevola C; Carnovale V; Antonelli F; Cernera G; Gelzo M; Terlizzi V
    Sci Rep; 2024 Jul; 14(1):17422. PubMed ID: 39075279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting weight gain in patients with cystic fibrosis on triple combination modulator.
    Stewart KL; Szczesniak R; Liou TG
    Pediatr Pulmonol; 2024 Jun; 59(6):1724-1730. PubMed ID: 38607242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor treatment in children aged 6-11 years with cystic fibrosis in a real-world setting.
    Daccò V; Rosazza C; Mariani A; Rizza C; Ingianni N; Nazzari E; Terlizzi V; Blasi FA; Alicandro G
    Pediatr Pulmonol; 2024 Nov; 59(11):2792-2799. PubMed ID: 38869349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis.
    Zemanick ET; Emerman I; McCreary M; Mayer-Hamblett N; Warden MN; Odem-Davis K; VanDevanter DR; Ren CL; Young J; Konstan MW;
    J Cyst Fibros; 2024 Jul; 23(4):676-684. PubMed ID: 38360461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
    Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
    Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A longitudinal study assessing the impact of elexacaftor/tezacaftor/ivacaftor on gut transit and function in people with cystic fibrosis using magnetic resonance imaging (MRI).
    Yule A; Ng C; Recto A; Lockwood F; Dellschaft NS; Hoad CL; Zagoya C; Mainz JG; Major G; Barr HL; Gowland PA; Stewart I; Marciani L; Spiller RC; Smyth AR
    J Cyst Fibros; 2024 Sep; 23(5):984-990. PubMed ID: 39242338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
    Flume PA; Biner RF; Downey DG; Brown C; Jain M; Fischer R; De Boeck K; Sawicki GS; Chang P; Paz-Diaz H; Rubin JL; Yang Y; Hu X; Pasta DJ; Millar SJ; Campbell D; Wang X; Ahluwalia N; Owen CA; Wainwright CE;
    Lancet Respir Med; 2021 Jul; 9(7):733-746. PubMed ID: 33581080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
    Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R;
    N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
    N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in a man with A559T and 3120+1G>CFTR variants.
    Mitchell E; Albon D
    Pediatr Pulmonol; 2024 Jul; 59(7):2009-2011. PubMed ID: 38607232
    [No Abstract]   [Full Text] [Related]  

  • 19. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist.
    Lee SE; Farzal Z; Daniels MLA; Thorp BD; Zanation AM; Senior BA; Ebert CS; Kimple AJ
    Am J Rhinol Allergy; 2020 Jul; 34(4):573-580. PubMed ID: 32168995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.
    Nichols DP; Paynter AC; Heltshe SL; Donaldson SH; Frederick CA; Freedman SD; Gelfond D; Hoffman LR; Kelly A; Narkewicz MR; Pittman JE; Ratjen F; Rosenfeld M; Sagel SD; Schwarzenberg SJ; Singh PK; Solomon GM; Stalvey MS; Clancy JP; Kirby S; Van Dalfsen JM; Kloster MH; Rowe SM;
    Am J Respir Crit Care Med; 2022 Mar; 205(5):529-539. PubMed ID: 34784492
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.